Industry News

Can Risk-Based Screening Save More Lives?

A new study published in JAMA suggests an alternative approach to lung cancer screening could better detect risk than current US Preventive Task Force (USPSTF) screening guidelines. Find out more here. (Source: First Report Managed Care, 5/16/16)[...]

Novartis Sees Good Results With New Oncology Drug

Novartis' experimental breast cancer pill, LEE011, has seen good results during clinical trial testing and will now seek approval with regulatory authorities worldwide. LEe011, or ribociclib will be in direct competition with Pfizer's Ibrance. More here. (Source: First Report Managed Care, 5/18/16)[...]

HealthEconomics.Com Continues As a Top Influencer During ISPOR’s 21st International Meeting

For the third consecutive day, HealthEconomics.Com has been distinguished by Symplur Hashtags, as a Top Influencer during ISPOR's 21st Annual International Meeting in Washington, D.C. HealthEconomics.Com is the only top-ranked centralized, digital CONNECTED COMMUNITY™ that serves as the indus[...]

Midwest CEPAC’s First Meeting Will Discuss ICER’s Report on Multiple Myeloma

On Thursday (5/26) the first meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) will be held in St. Louis, MO.  The Midwest CEPAC will take public votes rating the comparative clinical effectiveness and value of the drugs reviewed in the Institute for Clinica[...]

NICE Rejects New Roche Breast Cancer Drug

The National Institute for Health and Care Excellence (NICE) recently released draft guidance not recommending Perjeta, Roche's breast cancer drug. More evidence of long-term benefits would be needed to gain a recommendation. Read more here. (Source: First Report Managed Care, 5/20/16)[...]

Value Of EModels in Health Economics

eModels have the spirit of an app with dedicated interfaces and behavior designed to assist the user and make modeling and results communication journey as easy and clear as possible. Find out more here. (Source: Digital Health Outcomes Blog, 5/18/16)[...]

HealthEconomics.Com Again Named a Top Influencer During ISPOR DC.

Thanks to an extensive, and ever-growing CONNECTED COMMUNITY network, HealthEconomics.Com has once again been distinguished by Symplur as a Top Influencer at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting in Washington, DC, USA.&nbs[...]

Fixing the Data Paradox

Take a look Andy Slavitt's data paradox, as discussed at the recent Datapalooza conference, where physicians are overloaded on data entry and yet rampantly under informed. How do we fix this? Read more here. (Source: Kip Sullivan, The Health Care Blog, 5/16/16)[...]

Do You Really Need That Antibiotic?

In the most in-depth study yet to examine the use and misuse of antibiotics, nearly a third of prescribed antibiotics were found to be unnecessary - that's about 47 million unnecessary prescriptions a year! Read more. (Source: Lena H. Sun, The Washington Post, 5/3/16)[...]

How Pharma Makes Charitable Giving Profitable

It sounds great right? Pharma companies "have to" raise prices on prescription drugs, but they are aware that for many patients that means they won't be able to afford the drugs they need. So, here comes pharma to save the day... AGAIN! They start a charity group to help you pay your deductible on y[...]

How to Take Your Webinar From Good to Great

Webinars are an excellent tool to communicate information and expertise, generate and nurture leads, and cross- or up-sell products and services. HealthEconomics.Com is here to help YOU deliver great webinars with minimal effort. See more here. (Source: tHEORetically Speaking, 5/5/16)[...]

Inaugural Members Of Midwest CEPAC Appointed

Fourteen leading experts from the Midwest were recently named as the inaugural members of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC). Find out more here. (Source: ICER, 5/19/16)[...]

IRT Europe

Seventh National Accountable Care Organization (ACO) Summit

MACRA Could Hit Healthcare Industry Hard

Industry watchers weigh in on the CMS Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) proposed final rule. Read more. (Source: Tracey Walker, Managed Healthcare Executive, 5/11/16)[...]

What Does Mt Hood Have to Do With Diabetes Simulation?

Why is a diabetes and economics simulation modeling conference named after a mountain? Take a brief look at Diabetes Simulation Modeling beginning in 1999 at a ski lodge on the slopes of Mt Hood near Portland Oregon. Read more here. (Source: Philip Clarke, tHEORetically Speaking, 5/17/16)[...]

Call for Proposals: Improving State Health Reform Implementation

A call for proposals from the State Health Access Reform Evaluation (SHARE) program seeks to improve collective understanding of health reform at the state level in order to inform policy and the reform implementation process. Learn more here. (Source: Academy Health)[...]

Does Price Transparency Help to Lower Healthcare Spending?

According to a recent study published in the Journal of the American Medical Association found no association between price transparency and lower outpatient spending. Read more here. (Source: Zack Burdryk, FierceHealthFinance, 5/5/16)[...]

Naloxone – the Latest Old Drug With a Big New Price

Just as the Obama administration and Congress are pushing to make Naloxone, a drug used to reverse opioid overdose, more available, the drug has become the newest old drug to have a big new price. Read more here. (Source: Sarah Karlin-Smith, Politico, 5/16/16)[...]

ISPOR Call for Papers

ISPOR and ASHEcon are collaborating on an Initiative on Value Assessment Frameworks designed to inform the shift towards a value-driven health care system by promoting the development and dissemination of high-quality value assessment frameworks. As part of this initiative, Value in Health will publ[...]

Valeant Admits Price Hikes Were to Aggressive

After acquiring two heart drugs, Nitropress and Isuprel, Valeant Pharmaceuticals raised the price by 525% and 212% respectively. The company recently took part in a Senate committee hearing and has since admitted that they were too aggressive in increasing their prices and have come out with an enh[...]

Download CBI’s RWD Industry Snapshot

CBI had the opportunity to sit down with industry's foremost RWD thought leaders, asking them a variety of questions on the topic to better understand how bio/pharmceutical teams can collaborate and capture date in an aggregated form to continue to improve the value of products in the development wi[...]

Download: Rare Disease Collaboration Executive Summary

A complimentary executive summary that details key takeaways from the 2nd Rare Disease Collaboration Summit is now available for download, here. (Source: exl events)[...]

How Will Rising Drug Cost Affect Exclusion Lists?

A recent analysis from the Tufts Center for the Study of Drug Development finds that increasing drug prices in the U.S. could lead to payers and pharmacy benefit managers (PBMs) further reducing the amount of drugs eligible for reimbursement. Read more here. (Source: Laurie Toich, ajpb Live, 5/16/16[...]

CEA Registry Begins New Process for High Impact Economic Evaluations

The Tufts Medical Center Cost-Effectiveness Analysis (CEA) Registry will begin a new process for selected studies considered to be high impact economic evaluations. Read more here. (Source: CEA Registry, 5/16/16)[...]

Obama Under Pressure to Stem Drug Costs

With Congress unwilling to act, U.S. Rep. Lloyd Doggett is marshaling Democrats to pressure the Obama administration to stem the soaring costs of prescription drugs. Subscription needed to read more. (Source: Bill Lambrecht, San Antonio Express-News, 5/15/16)[...]

What Exactly Is Value-Based Pricing?

Regeneron CEO wants ICER to consider development risks when scoring drug value; ICER seeks intervention if price triggers 'alarm bell.' Article available for purchase here. (Source: Brenda Sandburg, Pink Sheet Daily, 5/13/16)[...]

Novartis Looks at New Sales Model for New Cancer Therapy

Novartis is looking at different sales models to market its experimental cancer treatment, CAR T-cell technology. Learn more about the CTL019 therapy and Novartis' expected sales model here. (Source: Jaimy Lee, MM&M, 5/16/16)[...]

Managed Care: High Drug Prices

CMS negotiation top pick for curbing high drug pricesEveryone in health care seems to be talking about drug prices. But what should be done to slow down their relentless rise?Allowing CMS to negotiate drug prices was the top answer of 432 MANAGED CARE readers and other health care executives who res[...]

Should Budget Assessment Be Part Of Value Assessment?

NPC recently ran a series around their recently unveiled, Guiding Practices for Patient-Centered Value Assessment. The last post was on budget impact assessments and their role in value assessments. See more here. (Source: NPC, 5/10/16)[...]


Stay Connected